<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70548">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959841</url>
  </required_header>
  <id_info>
    <org_study_id>M522101-J01</org_study_id>
    <nct_id>NCT01959841</nct_id>
  </id_info>
  <brief_title>Phase III Study of ASP2151 in Herpes Zoster Patients</brief_title>
  <official_title>Phase III Study of ASP2151 in Herpes Zoster Patients― A Double-blind, Valaciclovir-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with
      valaciclovir (VACV) 3000 mg in patients with herpes zoster.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, parallel-group study will be conducted to evaluate the efficacy
      and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in
      patients with herpes zoster. The efficacy will be evaluated for the primary endpoint defined
      as, &quot;the proportion of subjects achieving cessation of new lesion formation by Day 4 of
      study treatment&quot; to demonstrate the non-inferiority of ASP2151 to VACV. The safety will be
      evaluated based on adverse events, laboratory tests, vital signs, and ECGs.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects achieving cessation of new lesion formation by Day 4 of study treatment</measure>
    <time_frame>4days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of new lesion formation</measure>
    <time_frame>29days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete crusting</measure>
    <time_frame>29days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to healing</measure>
    <time_frame>29days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain resolution</measure>
    <time_frame>29days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virus disappearance</measure>
    <time_frame>29days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>ASP2151(200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151(400mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>valaciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151</intervention_name>
    <description>200 mg once daily or 400 mg once daily</description>
    <arm_group_label>ASP2151(200 mg)</arm_group_label>
    <arm_group_label>ASP2151(400mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valaciclovir</intervention_name>
    <description>1000 mg three times daily</description>
    <arm_group_label>valaciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1) Patients who have a rash associated with herpes zoster, and who can start receiving
        the study drug within 72 hours after onset of the rash

        Exclusion Criteria:

          1. Patients who are not expected to have an adequate response to oral antiviral
             medication

          2. An extreme decline in immune function

          3. Presence of serious complications

          4. Patients found to meet any of the following conditions based on laboratory tests
             performed within 14 days before informed consent:

               -  AST or ALT ≥ 2.5 x upper limit of normal

               -  Platelet count &lt; lower limit of normal

               -  Serum creatinine ≥ 1.5 mg/dL

               -  Creatinine clearance &lt; 50 mL/min

          5. Current or previous history of malignant tumor within 5 years before informed consent

          6. Diagnosis of autoimmune disease

          7. Evidence of bone marrow suppression
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
